NunaBio

News

07 July 2021

NunaBio demonstrates a novel technology for confirming the presence of E. coli

NunaBio Ltd. have successfully used their enhanced sensing platform to confirm the presence of a known sequence of DNA with confidence.

It has been previously demonstrated that detecting the presence of a DNA sequence using a short probe is less accurate due to low levels of fluorescence. By using our extended probe, multiple short sequences of target DNA are able to bind to the same unit area producing a much greater level of fluorescence. This allows us to distinguish between two or more DNA sequences with a high degree of accuracy.

This technique could be used to confirm the presence of different species of bacteria such as E. coli, with multiple species tested for simultaneously in a single array.

Working with NunaBio


We work through detail design, integration and initial testing, repeating this process to optimise the design before verification testing.

Our work is fully documented and a package of data and specifications can be assembled to allow scale up manufacture to start smoothly.  

We have extensive experience in Process Validation, Project Management to Phase 2 Manufacturing Criteria, Change Management and Quality Assurance to Regulatory standards (MHRA; FDA). 

Our operations management is led by a Lead Auditor qualified in Quality Management (ISO9001), Medical Devices (ISO13485), Laboratory Testing (ISO17025), Information Security (ISO27001), and Environmental Management (ISO14001).  

Let's talk